Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
Conditions
Adenocarcinoma - Stomach Cancer - Cancer of Esophagogastric Junction
Conditions: official terms
Adenocarcinoma - Stomach Neoplasms
Conditions: Keywords
Adenocarcinoma of the stomach and esophagogastric junction
Study Type
Interventional
Study Phase
Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic
Intervention
Name: FDG-PET-CT
Type: Procedure
Overall Status
Recruiting
Summary
This prospective study includes patients with histologically proven cancer of the esophagogastric junction (Siewert Type II and III) and the stomach. Aim of the study is to evaluate the accuracy of PET-CT for the preoperative assessment of lymph node metastasis. The evaluation includes a combination with standard diagnostic tools (endoluminal ultrasound, CT and diagnostic laparoscopy prior to neoadjuvant therapy). Standardized D2-lymphadenectomy is performed and individual lymph node stations (Nr 1-12 according to the Japanese classification) are histopathologically examined. Furthermore we evaluate the role of the PET-CT for early metabolic response evaluation in patients receiving neoadjuvant chemotherapy.

- Trial with surgical intervention
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion criteria:

- Histological prove of adenocarcinoma of the stomach.

Exclusion criteria:

- Recurrent gastric carcinoma

- No informed consent

- Previous malignancy (exception: thyroid, bladder in situ, Cervix in situ)
Location
Zurich, Switzerland
Status: Recruiting
Start Date
October 2008
Sponsors
Kuno Lehmann
Source
University of Zurich
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page